RHINOLONE NASAL SPRAY 55 MICROGRAMS/DOSE [SIN17481P]
Active ingredients: RHINOLONE NASAL SPRAY 55 MICROGRAMS/DOSE
Last updated 24 April 2026
Product Info
RHINOLONE NASAL SPRAY 55 MICROGRAMS/DOSE
[SIN17481P]
Product information
Active Ingredient and Strength | TRIAMCINOLONE ACETONIDE - 55 MCG/DOSE |
Dosage Form | SPRAY, SUSPENSION |
Manufacturer and Country | FARMACLAIR - FRANCE |
Registration Number | SIN17481P |
Licence Holder | NOVEM HEALTHCARE PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | R01AD11 |
Prescription-only Medicines with Exemptions for Supply without Prescription | As an intranasal spray containing not more than 55 mcg/actuation
|
Indication
4.1. Therapeutic indications
RHINOLONE is indicated for the treatment of nasal symptoms of seasonal and perennial allergic rhinitis in adults and children aged 4 years and older.
Dosing
4.2. Posology and method of administration
Recommended doses
Adults and Children 12 years of age and older: The recommended starting and maximum dose is 220 mcg per day as two sprays in each nostril once daily.
Children 4 to 12 years of age: The recommended starting dose is 110 mcg per day given as one spray in each nostril once daily.
The maximum recommended dose is 220 mcg per day as two sprays per nostril once daily.
RHINOLONE Nasal Spray is not recommended for children under 4 years of age since adequate numbers of patients have not been studied in this age group.
Individualization of Dosage
It is always desirable to titrate an individual patient to the minimum effective dose to reduce the possibility of side effects. In adults, when the maximum benefit has been achieved and symptoms have been controlled, reducing the dose to 110 mcg per day (one spray in each nostril once a day) has been shown to be effective in maintaining control of the allergic rhinitis symptoms in patients who were initially controlled at 220 mcg/day.
In children four to twelve years of age, the recommended starting dose is 110 mcg per day given as one spray in each nostril once daily. The maximum recommended daily dose in children 4 to 12 years of age is 220 mcg per day (two sprays in each nostril once daily). Some patients who do not achieve maximum symptom control at a dose of 110 mcg per day may benefit from a dose of 220 mcg given as two sprays in each nostril once daily. The minimum effective dose should be used to ensure continued control of symptoms. Once symptoms are controlled, paediatric patients may be able to be maintained on 110 mcg per day (1 spray in each nostril once daily).
An improvement in some patient symptoms may be seen within the first day of treatment, and generally, it takes one week of treatment to reach maximum benefit. Initial assessment for response should be made during this time frame and periodically until the patient’s symptoms are stabilized. If adequate relief of symptoms has not been obtained after 3 weeks of treatment, RHINOLONE Nasal Spray should be discontinued. (see sections 4.4, 4.8 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information)
Method of Administration
See section 10 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
Contraindications
4.3. Contraindications
Hypersensitivity to triamcinolone or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.